Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation

Area of Science:

• Cardiovascular Genetics
• Pharmacogenomics
• Epidemiology

Background:

• Atrial fibrillation (AF) is a common arrhythmia with serious health consequences.
• The impact of lipid-lowering drugs, specifically PCSK9 inhibitors (PCSK9i) and statins (HMG-CoA reductase inhibitors), on AF risk is under investigation.
• Mendelian randomization (MR) can explore causal links between genetic predisposition to drug targets and disease risk.

Purpose of the Study:

• To investigate the causal relationship between genetically predicted PCSK9 inhibition and AF risk.
• To examine the causal relationship between genetically predicted HMG-CoA reductase inhibition and AF risk.
• To compare the effects of PCSK9i and statins on AF risk using genetic data.

Main Methods:

• Employed MR using summary-level genome-wide association study data.
• Utilized single-nucleotide polymorphisms associated with lower LDL-C as instrumental variables.
• Applied various MR techniques and sensitivity analyses for robust causal inference.

Main Results:

• Genetically predicted PCSK9 inhibition was associated with a reduced risk of AF (OR = 0.92, p = 0.01).
• Genetically predicted HMG-CoA reductase inhibition showed no statistically significant association with AF risk (OR = 1.11, p = 0.05).
• Sensitivity analyses supported the primary findings.

Conclusions:

• Genetically predicted PCSK9 inhibition, unlike HMG-CoA reductase inhibition, is linked to a lower risk of AF.
• Findings suggest a potential causal protective effect of PCSK9 inhibitors against AF.
• Results support considering PCSK9 inhibitors for AF prevention in patients with dyslipidemia.